Patents by Inventor Shengfang Jin

Shengfang Jin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Resistance sequences and uses thereof
    Patent number: 6933105
    Abstract: Increased expression of resistance sequences is associated with drug resistance of certain cells (e.g., cancer cells). The invention provides methods for identifying drug resistant cells by measuring the expression or activity of resistance genes (e.g., semaphorin D, B94, mel-14 antigen, 24p3, proliferin, or maspin), methods for identifying modulators of drug resistance, and methods for modulating drug resistance by modulating the expression or activity of resistance sequences.
    Type: Grant
    Filed: January 31, 2001
    Date of Patent: August 23, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Shengfang Jin
  • Chk1 and uses thereof
    Publication number: 20040091948
    Abstract: Increased expression of Chk1 is associated with drug resistance of certain cells (e.g., cancer cells). The invention provides methods for identifying drug resistant cells by measuring the expression or activity of Chk1, methods for identifying modulators of drug resistance, and methods for modulating drug resistance by modulating the expression or activity of Chk1.
    Type: Application
    Filed: November 6, 2003
    Publication date: May 13, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Andrew W. Shyjan, Mark Williamson, Shengfang Jin
  • Chk1 and uses thereof
    Patent number: 6723498
    Abstract: Increased expression of Chk1 is associated with drug resistance of certain cells (e.g., cancer cells). The invention provides methods for identifying drug resistant cells by measuring the expression or activity of Chk1, methods for identifying modulators of drug resistance, and methods for modulating drug resistance by modulating the expression or activity of Chk1.
    Type: Grant
    Filed: June 30, 1999
    Date of Patent: April 20, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Andrew W. Shyjan, Mark Williamson, Shengfang Jin
  • DR6 and uses thereof
    Patent number: 6423494
    Abstract: Increased expression of DR6 is associated with drug resistance of certain cells (e.g., cancer cells). The invention provides methods for identifying drug resistant cells by measuring the expression or activity of DR6, methods for identifying modulators of drug resistance, and methods for modulating drug resistance by modulating the expression or activity of DR6.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: July 23, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Shengfang Jin, Andrew W. Shyjan, Christophe Van Huffel
  • Resistance sequences and uses thereof
    Publication number: 20010034332
    Abstract: Increased expression of resistance sequences is associated with drug resistance of certain cells (e.g., cancer cells). The invention provides methods for identifying drug resistant cells by measuring the expression or activity of resistance genes (e.g., semaphorin D, B94, mel-14 antigen, 24p3, proliferin, or maspin), methods for identifying modulators of drug resistance, and methods for modulating drug resistance by modulating the expression or activity of resistance sequences.
    Type: Application
    Filed: January 31, 2001
    Publication date: October 25, 2001
    Inventor: Shengfang Jin